7 recruiting, 2 not yet recruiting, 1 active not recruiting, 1 withdrawn. 7 Phase 1, 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Recruiting 6, Not yet recruiting 1 |
| Phase 2 | 5 | Recruiting 2, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Recurrent Glioblastoma, IDH-Wildtype: new trials by email Literature Review of Recurrent Glioblastoma, IDH-Wildtype trials Research Report on Recurrent Glioblastoma, IDH-Wildtype
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma Cerebraca wafer, Temozolomide (for relapsed malignant glioma) - Recurrent Glioblastoma, IDH-Wildtype | Phase 2 / Phase 3 | Not yet recruiting | Everfront Biotech Co., Ltd. | 175 | 2027-04-01 | 2026-09-10 |
| Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma Actinium Ac 225 Lintuzumab, Biospecimen Collection, Cemiplimab - Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 30 | 2026-12-04 | 2026-06-12 |
| GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma Biospecimen Collection, Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102, Computed Tomography - Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Recruiting | Mayo Clinic | 36 | 2026-08-03 | 2026-10-01 |
| Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells, Biopsy Procedure, Biospecimen Collection - Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype | Phase 1 | Recruiting | City of Hope Medical Center | 24 | 2026-05-26 | 2026-10-23 |
| Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma Biospecimen Collection, Computed Tomography, Intensity-Modulated Radiation Therapy - Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2025-07-30 | 2026-10-21 |
| ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801 - Glioblastoma, Glioblastoma, IDH-Wildtype | Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 50 | 2025-07-28 | 2026-09-18 |
| Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma Atezolizumab, Biospecimen Collection, Magnetic Resonance Imaging - Recurrent Glioblastoma, IDH-Wildtype | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-04-30 | 2024-12-30 | |
| Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration - Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma | Phase 1 | Recruiting | Northwestern University | 22 | 2024-07-23 | 2026-09-09 |
| Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy Allogeneic Adipose-derived Mesenchymal Stem Cells, Biospecimen Collection, Craniotomy - Recurrent Glioblastoma, IDH-Wildtype, Recurrent Astrocytoma, IDH-Mutant, Grade 4 | Phase 1 | Recruiting | Mayo Clinic | 20 | 2023-06-16 | 2026-04-02 |
| Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment Biospecimen Collection, Magnetic Resonance Imaging, Placebo Administration - Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 97 | 2023-03-20 | 2026-10-23 |
| Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma Biospecimen Collection, Efineptakin alfa, Pembrolizumab - High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype | Phase 2 | Active not recruiting | Mayo Clinic | 53 | 2023-01-24 | 2026-10-05 |
Glioblastoma (11) · Astrocytoma (4) · Gliosarcoma (4) · Lymphoma, Follicular (1)
Glioma (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Neoplasms, Germ Cell and Embryonal (11) · Neoplasms, Glandular and Epithelial (11) · Neoplasms, Nerve Tissue (11) · Neoplasms, Neuroepithelial (11) · Neuroectodermal Tumors (11) · Astrocytoma (7) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1)
Specimen Handling (10) · Magnetic Resonance Spectroscopy (9) · Surgical Procedures, Operative (3) · Temozolomide (3) · 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (2) · Biopsy (2) · pembrolizumab (2) · Actinium (1) · Craniotomy (1) · Fluorodeoxyglucose F18 (1) · Leukapheresis (1) · Photons (1) · Radiotherapy, Intensity-Modulated (1) · Tiragolumab (1) · X-Rays (1)
National Cancer Institute (NCI) (4) · Mayo Clinic (3) · City of Hope Medical Center (1) · Everfront Biotech Co., Ltd. (1) · Jonsson Comprehensive Cancer Center (1) · Northwestern University (1)
United States (9)
Megan Mantica (2) · Alfredo Quinones-Hinojosa, MD (1) · Behnam Badie (1) · Jana L Portnow (1) · Jian L Campian, MD, PhD (1) · Jian L. Campian, MD, PhD (1) · Karan Dixit, MD (1) · Phioanh Nghiemphu (1) · Stephanie M Yoon (1)
UM1CA186690 (2), UM1CA186717 (2), P30CA033572 (1), P30CA060553 (1), R01CA279984 (1), R01CA288862 (1)